Stock Events

Stock Events

Corcept Therapeutics 

€94.40
138
-€2.44-2.52% Thursday 06:01

Statistics

Day High
94.4
Day Low
94.4
52W High
107.05
52W Low
27.89
Volume
-
Avg. Volume
-
Mkt Cap
10.2B
P/E Ratio
262.51
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.3
0.07
0.44
0.81
Expected EPS
0.81354
Actual EPS
N/A

Financials

13.08%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
659.43MRevenue
86.27MNet Income

Analyst Ratings

93.03Average Price Target
The highest estimate is 125.20.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
0%
Sell
20%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HTD.F. It's not an investment recommendation.
NVIDIA
30
NVDA
Microsoft
24
MSFT
Apple
22
AAPL
Realty Income
19
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes in the pharmaceuticals space, focusing on therapies that could directly compete with Corcept's treatments in endocrine and metabolic diseases.
Pfizer
PFE
Mkt Cap159.36B
Pfizer operates in various therapeutic areas, including endocrinology, potentially competing with Corcept's hormone-related therapies.
Merck
MRK
Mkt Cap366B
Merck is involved in developing medications for a wide range of conditions, including those that could compete with Corcept's focus areas.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb develops drugs in multiple therapeutic areas, including those that could compete with Corcept's products in hormonal and metabolic diseases.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a broad portfolio of drugs, including treatments for endocrine disorders, directly competing with Corcept's market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on innovative therapeutics, including endocrine and metabolic disorders, which could compete with Corcept's therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, known for its work in antiviral drugs, also explores treatments in other areas that could compete with Corcept's focus on metabolic and endocrine disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals focuses on developing drugs for a wide range of diseases, including potential competition in the endocrine and metabolic disorder space.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, potentially including those that compete with Corcept's niche in hormonal therapies.

About

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Show more...
CEO
Joseph K. Belanoff
Employees
730
Country
United States
ISIN
US2183521028
WKN
000529882

Listings

MI
IT
1CORT.MI
XNAS
US
CORT
STU
DE
HTD.STU
MU
DE
HTD.MU

0 Comments

Share your thoughts

FAQ

What is Corcept Therapeutics stock price today?▼
The current price of HTD.F is €94.40 EUR — it has decreased by -2.52% in the past 24 hours. Watch Corcept Therapeutics stock price performance more closely on the chart.
What is Corcept Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Corcept Therapeutics stocks are traded under the ticker HTD.F.
Is Corcept Therapeutics stock price growing?▼
HTD.F stock has fallen by -3.83% compared to the previous week, the month change is a -1.28% fall, over the last year Corcept Therapeutics has showed a +59.3% increase.
What is Corcept Therapeutics market cap?▼
Today Corcept Therapeutics has the market capitalization of 10.2B
When is the next Corcept Therapeutics earnings date?▼
Corcept Therapeutics is going to release the next earnings report on November 04, 2026.
What were Corcept Therapeutics earnings last quarter?▼
HTD.F earnings for the last quarter are 0.31 EUR per share, whereas the estimation was 0.02 EUR resulting in a +1,383.25% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Corcept Therapeutics revenue for the last year?▼
Corcept Therapeutics revenue for the last year amounts to 659.43M EUR.
What is Corcept Therapeutics net income for the last year?▼
HTD.F net income for the last year is 86.27M EUR.
How many employees does Corcept Therapeutics have?▼
As of September 04, 2026, the company has 730 employees.
In which sector is Corcept Therapeutics located?▼
Corcept Therapeutics operates in the Health & Wellness sector.
When did Corcept Therapeutics complete a stock split?▼
Corcept Therapeutics has not had any recent stock splits.
Where is Corcept Therapeutics headquartered?▼
Corcept Therapeutics is headquartered in REDWOOD CITY, United States.